Nxera Pharma Co., Ltd.
Announcement of Exclusive License Agreement for Fabry Disease Therapeutic Candidate lucerastat in Japan and Parts of the Asia-Pacific Region
Exercised option to acquire exclusive development and commercialization rights for lucerastat in Japan and certain APAC territories, including Korea and Taiwan, and will advance development in the designated territories. Paid an initial upfront of 7 million Swiss francs and will cooperate with global Phase 3 advancement.
Key Figures
- Upfront payment: 7 million CHF (approx. 1,334 million yen)
- Territories: Japan, South Korea, Taiwan and certain other Asia-Pacific territories (excluding China)
- Long-term outlook: Cooperation in the global Phase 3 trial program and development toward regulatory submissions
AI要約
Overview of the Partnership
Nxera Pharma Co., Ltd. has exercised an option to license lucerastat from Idorsia Pharmaceuticals, acquiring exclusive development and commercialization rights for lucerastat in certain APAC territories including Japan, South Korea and Taiwan. An upfront payment of 7 million CHF will be made, and Nxera Pharma will cooperate with the advancement of the global Phase 3 program. Idorsia will receive royalties based on net sales in the designated territories. The trials are part of the global Phase 3 program including FAB-KLEAR, and Nxera Pharma will manage clinical development operations in Japan.
Impact on Business Strategy and Future Outlook
Lucerastat is believed to potentially slow Fabry disease progression by inhibiting Gb3 production, and Phase 3 data suggests it may delay deterioration of renal function. Under a global development strategy aligned with FDA/EMA considerations, participation in the approval-seeking program is intended to expand Nxera Pharma’s portfolio in the rare disease area across Japan and APAC.
Nxera Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
